Jack A. Khattar is the founder of our company and has served as our President, CEO and Secretary and a Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions during that time as a board member, President and CEO of Shire Laboratories Inc., the drug delivery subsidiary... of Shire plc. From 1999 to 2004, he also served as a member of Shire plc’s executive committee. Prior to that, Mr. Khattar served as an executive officer and the Chairman of the management committee at CIMA Labs Inc. (CIMA), a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex and Kodak in various locations, including the United States, Europe and the Middle East. Mr. Khattar currently serves on the boards of directors of Navitor Pharmaceuticals, LLC a privately-held development stage biotechnology company, and on the advisory board of New Rhein Healthcare, a private equity firm. Mr. Khattar also serves as Chairman of the board of directors of scPharmaceuticals and Cognition Therapeutics Inc., two publicly traded pharmaceutical companies. Mr. Khattar earned his degrees in Marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania. ...Read More +

Timothy C. Dec has served as our Senior Vice-President of Finance since August 2021. Mr. Dec has more than 35 years of experience in accounting and finance across many industries, including healthcare. His experience includes serving in chief financial officer or other senior financial executive roles ... at three publicly traded companies listed on Nasdaq, and with private equity-backed companies. Most recently, from April 2015 to July 2021, Mr. Dec was Chief Financial Officer of OpGen, Inc., a Nasdaq listed company engaged in the development and commercialization of molecular microbiology solutions to help combat infectious diseases. Prior to joining OpGen, Mr. Dec served as Senior Vice President and Chief Financial Officer for Clubwidesports, LLC, a start-up sports management software company, from January 2014 to April 2015. From August 2007 to December 2012, Mr. Dec served as Senior Vice President and Chief Financial Officer of Fortress International Group, Inc., a publicly traded company. From June 2006 to August 2007, Mr. Dec was Senior Vice President, Chief Financial Officer of Presidio Networked Solutions, a private company, and from June 1999 to June 2006, was Senior Vice President, Chief Accounting Officer and Treasurer of Broadwing Corporation (formerly Corvis Corporation), a publicly traded company. Mr. Dec also has public accounting firm experience and served as an Adjunct Professor teaching M.B.A courses in finance at Mount St. Mary’s University from January 2013 to August 2017. Mr. Dec received his B.S. in accounting from Mount St. Mary’s University and an M.B.A. in finance from American University. ...Read More +

Kevin T. Anderson, Esq., has served as Compliance Officer since 2012. Mr. Anderson previously held positions as Compliance Officer and Vice President of Human Resources at Xanodyne Pharmaceuticals, as General Counsel for U.S. Commercial Operations at Shire Pharmaceuticals, and ...as a manager with the Emerging Business Group at Ernst & Young.
Mr. Anderson earned his BSBA with majors in Accounting and Finance from Ohio Northern University and a Juris Doctorate degree from the University of Cincinnati College of Law. ...Read More +

Padmanabh P. Bhatt, Ph.D, has served as our Senior Vice President of Intellectual Property and Chief Scientific Officer since March 2012. Prior to that, he served as our Vice President of Pharmaceutical Sciences beginning in 2005. From 2003 to 2005, Dr. Bhatt was Vice President of Advanced Drug ... Delivery at Shire Laboratories, Inc. From 2001 to 2003, Dr. Bhatt served as Vice President of Research and Development and Chief Technology Officer at Point Biomedical Corporation. From 1996 to 2001, he served at ALZA (now a Johnson & Johnson company) in various positions, from Product Development Manager to Director of Technical Development. Prior to that time, Dr. Bhatt held positions as Research Specialist and Group Leader of Novel Drug Delivery at Dow Corning Corporation (from 1992 to 1996) and Senior Scientist at Hercon Laboratories (from 1989 to 1992).
Dr. Bhatt earned his B.Pharm and M.Pharm degrees from the University of Bombay, India. He also holds M.S. and Ph.D. degrees in Pharmaceutical Chemistry from the University of Kansas. ...Read More +

Jeff Bozick has served as our Senior Vice President of Supply Chain since May 2021. Prior to that, he served as our Executive Director of Supply Chain upon joining in November 2011. Mr. Bozick has over 30 years of experience in Life Science Supply Chain Management. From 2006 to 2011, he was ...Director of Outsourced Supply Operations at Eisai Inc. From 2004 to 2006, Mr. Bozick was the Director of Supply Operations at Ligand Pharmaceuticals until its Oncology division was acquired by Eisai. From 1997 to 2004, he served as Director of Manufacturing and Materials at Alliance Pharmaceutical Corp. Prior to joining Alliance, Mr. Bozick held various supply chain and consulting positions at Hybritech Inc., Beckman Instruments, and La Jolla Pharmaceuticals. ...Read More +

Roman Bradel, Ph.D. has served as our Vice President of Regulatory Affairs since March 2024. Dr. Bradel possesses over 30 years of industry experience, including 25 years in positions of regulatory leadership and offers a very diverse regulatory background with experience in all dosage forms of ... pharmaceuticals, their respective submissions, and clinical paths.
Previous leadership roles included serving as the Head of Regulatory Affairs for both Oryn Therapeutics, and Prolacta Bioscience. Dr. Bradel was also responsible for supporting Humira® (adalumimab) during his tenure with AbbVie Inc. Dr. Bradel holds a B.S. in Physical Chemistry and earned his Ph.D. in Chemistry from the Technical University Berlin, in Berlin, Germany, with his thesis focused on Biopolymers for controlled-release pharmaceuticals. ...Read More +

Todd Horich was appointed Senior Vice President and Chief Commercial Officer in March 2026. Dr. Horich joined Supernus as the first commercial employee in 2010, responsible for building and leading the Marketing Team, as well as New Product Planning and Commercial Development. He has led the Market Access Team since May 2021, and Commercial Operations Team since December 2023, playing an integral leadership role in ... the build out of the organization, integration of corporate acquisitions and alliances, and successful launches of Trokendi XR^®, Oxtellar XR^®, Qelbree^®, and Onapgo^®. Prior to joining Supernus, Dr. Horich held various positions of increasing responsibility with Novartis Pharmaceuticals Inc., as well as Director level positions with Vanda Pharmaceuticals and Medimmune, Inc, and has 25 years of commercial leadership experience across multiple disease states in retail and specialty pharma.

Dr. Horich earned his Ph.D in Pharmaceutical Sciences from the University of Maryland, and a Master of Business Administration from the University of Baltimore. He also holds an MS and a BS in Biological Sciences from the University of Maryland. He has received numerous awards and accolades throughout his career and was recognized in 2017 by Pharmaceutical Executive Magazine as an Emerging Pharmaceutical Leader. ...Read More +

Frank Mottola was promoted to Senior Vice President, Chief Technical Operations Officer in June 2025. Previously, he served as Senior Vice President, Quality, GMP Operations and Information Technology beginning in 2020 and Vice President of Quality, GMP Operations and Information Technology from ... 2017 to 2020. From 2014-2017, he served as Vice President of Quality and GMP Operations. Initially he joined Supernus as Director of Quality in 2005, responsible for initiating Quality Systems at the company’s inception. Prior to that time, Mr. Mottola was the Director of Quality at Able Laboratories and previously held positions at Ortho Clinical Diagnostics (Johnson & Johnson). He has 24 years of experience in the pharmaceutical industry and holds a Bachelor’s degree in Biology and Business Administration while attending Rutgers University and Walden University. ...Read More +

Taylor Raiford has served as our Senior Vice President of Sales since May 2021. From 2012 to 2014, he served as our National Sales Director and has been responsible for building and leading the Sales Force since the inception of the Commercial Organization. In addition to the Sales Force, his ... responsibilities include Sales Operations and Sales Training. Prior to joining Supernus, Mr. Raiford held various positions at Shire Pharmaceuticals from 1995 to 2011, including Director-level positions in Sales, Sales Training/Leadership Development, and Marketing. Mr. Raiford earned his B.A. in Communications, Public Relations from North Carolina State University. ...Read More +

Bryan A. Roecklein, Ph.D, joined in July 2015 as our Vice President of Corporate Development. Most recently he was a member of the U.S. Executive Team at Meda Pharmaceuticals, leading the Corporate Development function. Prior to that, he was Vice President of Marketing and Business ... Development, with responsibilities covering Marketing, Access, Trade and Acquisition Strategy. From 2001 to 2011, at MedPointe, then Meda Pharmaceuticals, Dr. Roecklein held various positions with increasing responsibility in Portfolio Management, New Product Planning, Marketing, Medical Education and Commercial Development. From 1998 to 2001, Dr. Roecklein led commercial development at Kimeragen and ValiGene, and from 1995-1998, he was an independent Investigator at the Fred Hutchinson Cancer Research Center.
Dr. Roecklein earned his B.S. from University of Maryland, College Park and Ph.D in Molecular, Cellular, and Developmental Biology from the University of Colorado Boulder. ...Read More +

Jonathan Rubin, MD, MBA, has been the Chief Medical Officer and Senior Vice President of Research & Development at Supernus Pharmaceuticals, Inc. since January 1, 2021. Before joining the Company on February 10, 2020, as Senior Vice-President, Clinical Research and ... Medical Affairs, Dr. Rubin was Chief Medical Officer of Atentiv, Inc. from 2018 to 2020, where he was responsible for clinical strategy and the design of clinical trials. From 2017 to 2018, Dr. Rubin was a clinical consultant to Chondrial Therapeutics, Inc. responsible for developing clinical strategy and trials. From 2013 to 2017, Dr. Rubin was Chief Medical Officer of Alcobra, Inc., where he was responsible for oversight of the company’s clinical development, medical affairs, biometrics and pharmacovigilance departments, and he participated in the completion of two Phase III studies in ADHD and assisted with orphan drug and fast track designations for product candidates. From 2007 to 2013, Dr. Rubin was Medical Director of Clinical Development and Medical Affairs for Shire Pharmaceuticals, where he supported the company’s ADHD portfolio and assisted with the design, execution and interpretation of Phase II, Phase IIIB and Phase IV studies. Prior to entering the biopharmaceutical industry, Dr. Rubin was in private practice as a Developmental-Behavioral and General Pediatrician for 16 years. Dr. Rubin was a pediatric resident at Albert Einstein/Montefiore Hospital in the Bronx, New York and a fellow in ambulatory pediatrics at Boston’s Children Hospital. Dr. Rubin received his M.D. from the University of Connecticut School of Medicine, his Master of Business Administration from the Columbia School of Business and his Bachelor of Science in molecular biophysics and biochemistry from Yale University. ...Read More +